Nafamostat mesilate attenuates colonic inflammation and mast cell infiltration in the experimental colitis

International Immunopharmacology

Volumn 11, Issue 4, 2011, Pages 412-417

  Cho, Eun Young ^b   Choi, Suck Chei ^b   Lee, Sun Hee ^c   Ahn, Ji Young ^a   Im, Lee Rang ^a   Kim, Jun Ho ^a   Xin, Mingjie ^a   Kwon, Se Uk ^a   Kim, Dae Ki ^c   Lee, Young Mi ^a  

^a Wonkwang University   (South Korea)

^b Wonkwang University School of Medicine   (South Korea)

^c Chonbuk National University Medical School   (South Korea)

Author keywords

Dextran sulfate sodium; Inflammatory bowel disease; Mast cells; Nafamostat mesilate; Serine proteases

Indexed keywords

CHYMASE; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; MESALAZINE; MYELOPEROXIDASE; NAFAMSTAT MESILATE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CELL INFILTRATION; COLITIS; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVITY; FEMALE; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECTUM HEMORRHAGE; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CELL COUNT; CHYMASES; COLITIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GUANIDINES; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA; MAST CELLS; MICE; MICE, INBRED BALB C; PEROXIDASE;

EID: 79952737759     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.12.008     Document Type: Article

References (27)

1. Fiocchi C. Inflammatory bowel disease; etiology and pathogenesis. Gastroenterology 1998;115:182-205. (Pubitemid 28307304)
2. Hyams JS. Inflammatory bowel disease. Pediatr Rev 2000;21:291-5.
3. Danese S, Sans M, Fiocchi C. Inflammatory bowel disease; the role of environmental factors. Autoimmun Rev 2004;3:394-400. (Pubitemid 38993362)
4. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002;15:79-94. (Pubitemid 34052583)
5. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 1999;11:648-56.
6. Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999;94:1643-9. (Pubitemid 29260459)
7. Araki Y, Andoh A, Fujiyama Y, Bamba T. Development of dextran sulphate sodium-induced experimental colitis is suppressed in genetically mast cell-deficient Ws/Ws rats. Clin Exp Immunol 2000;119:264-9. (Pubitemid 30073028)
8. King T, Biddle W, Bhatia P, Moore J, Miner Jr PB. Colonic mucosal mast cell distribution at line of demarcation of active ulcerative colitis. Dig Dis Sci 1992;37:490-5.
9. Redington AE, Polosa R, Walls AF, Howarth PH, Holgate ST. Role of mast cell and basophil in asthma. Chem Immunol 1995;62:22-59.
10. Stoyanova II, Gulubova MV. Mast cells and inflammatory mediators in chronic ulcerative colitis. Acta Histochem 2002;104:185-92. (Pubitemid 34606365)
11. Jippo T, Tsujino K, Kim HM, Kim DK, Lee YM, Nawa Y, et al. Expression of mast cell-specific proteases in tissues of mice studied by in situ hybridization. Am J Pathol 1997;150:1373-82. (Pubitemid 27152655)
12. Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci USA 1986;83:4464-8. (Pubitemid 16057069)
13. Cenac N, Coelho AM, Nguyen C, Compton S, Andrade-Gordon P, MacNaughton WK, et al. Induction of intestinal inflammation in mouse by proteinase-activated receptor-2. Am J Pathol 2002;161:1903-15. (Pubitemid 35265547)
14. Kim JA, Choi SC, Yun KJ, Kim DK, Han MK, Seo GS, et al. Expression of protease-activated receptor 2 in ulcerative colitis. Inflamm Bowel Dis 2003;9:224-9.
15. Ishida K, Takai S, Murano M, Nishikawa T, Inoue T, Murano N, et al. Role of chymase-dependent matrix metalloproteinase-9 activation in mice with dextran sodium sulfate-induced colitis. J Pharmacol Exp Ther 2008;324:422-6. (Pubitemid 351185847)
16. Issekutz AC, Roland DM, Patrick RA. The effect of FUT-175 (Nafamstat Mesilate) on C3a, C4a and C5a generation in vitro and inflammatory reactions in vivo. Int J Immunopharmacol 1990;12:1-9. (Pubitemid 20034205)
17. Mori S, Itoh Y, Shinohata R, Sendo T, Oishi R, Nishibori M. Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J Pharmacol Sci 2003;92: 420-3. (Pubitemid 37086724)
18. Aoyama T, Ino Y, Ozeki M, Oda M, Sato T, Koshiyama Y, et al. Pharmacological studies of FUT-175, nafamstat mesilate. I Inhib protease activity vitro vivo experiments. Jpn J Pharmacol 1984;35:203-27. (Pubitemid 14124814)
19. Hitomi Y, Fujii S. Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor. Int Arch Allergy Appl Immunol 1982;69: 262-7. (Pubitemid 12004555)
20. Chen CC, Wang SS, Lee FY. Action of antiproteases on the inflammatory response in acute pancreatitis. JOP 2007;8:488-94.
21. Isozaki Y, Yoshida N, Kuroda M, Handa O, Takagi T, Kokura S, et al. Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis. Scand J Gastroenterol 2006;41:944-53. (Pubitemid 43995470)
22. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. Novel method in the induction of reliable exprerimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694-702. (Pubitemid 20069706)
23. Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporine. Dig Dis Sci 1993;38:1722-34. (Pubitemid 23271431)
24. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984;87:1344-50.
25. Kakizoe E, Li SH, Kobayashi Y, Nishikori Y, Dekio S, Okunishi H. Increases in mast cells and chymase in fibroproliferative paws of collagen-induced arthritic mice. Inflamm Res 1999;48:318-24. (Pubitemid 29329294)
26. Boughton-Smith NK, Wallace JL, Morris GP, Whittle BRJ. The effect of antiinflammatory drugs on eicosanoid formation in a chronic model of inflammatory bowel disease. Br J Pharmacol 1988;94:65-72.
27. Noguchi S, Nakatsuka M, Konishi H, Kamada Y, Chekir C, Kudo T. Nafamostat mesilate suppresses NF-kappaB activation and NO overproduction in LPS-treated macrophages. Int Immunopharmacol 2003;3:1335-44. (Pubitemid 36936769)